Skip to content
10-K

Annual Report

vTv Therapeutics Inc. VTVT

0001641489-26-000010

← back to feed
Filed
Mar 10, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Operating Cash Flow FY 2025 · Dec 31, 2025 −$25.26M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$25.31M
Operating Cash Flow FY 2025 · Dec 31, 2023 −$19.08M
Cash And Equivalents FY 2025 · Dec 31, 2025 $88.93M
Cash And Equivalents FY 2025 · Dec 31, 2024 $36.75M
Stockholders Equity FY 2025 · Dec 31, 2025 $64.44M
Stockholders Equity FY 2025 · Dec 31, 2024 $12.2M
Current Liabilities FY 2025 · Dec 31, 2025 $6.64M
Current Liabilities FY 2025 · Dec 31, 2024 $5.2M
Total Liabilities FY 2025 · Dec 31, 2025 $25.46M
Total Liabilities FY 2025 · Dec 31, 2024 $23.97M
Current Assets FY 2025 · Dec 31, 2025 $89.89M
Current Assets FY 2025 · Dec 31, 2024 $38.11M
Total Assets FY 2025 · Dec 31, 2025 $89.9M
Total Assets FY 2025 · Dec 31, 2024 $38.27M
Sga Expense FY 2025 · Dec 31, 2025 $14.95M
Sga Expense FY 2025 · Dec 31, 2024 $13.65M
Sga Expense FY 2025 · Dec 31, 2023 $11.91M
Rd Expense FY 2025 · Dec 31, 2025 $17.86M
Rd Expense FY 2025 · Dec 31, 2024 $11.55M
Rd Expense FY 2025 · Dec 31, 2023 $13.6M
Net Income FY 2025 · Dec 31, 2025 −$26.97M
Net Income FY 2025 · Dec 31, 2024 −$18.46M
Net Income FY 2025 · Dec 31, 2023 −$20.25M
Operating Income FY 2025 · Dec 31, 2025 −$32.81M
Operating Income FY 2025 · Dec 31, 2024 −$24.18M
Operating Income FY 2025 · Dec 31, 2023 −$25.5M
Revenue FY 2025 · Dec 31, 2025 $0
Revenue FY 2025 · Dec 31, 2024 $1.02M
Revenue FY 2025 · Dec 31, 2023 $0